Arvest Investments’s Bristol-Myers Squibb BMY Stock Holding History

Arvest Investments’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$392K	Sell	6,805 -126	-2%	-$7.24K	0.05%	158
2026 Q1	$420K	Sell	6,931 -133	-2%	-$7.75K	0.06%	144
2025 Q4	$381K	Sell	7,064 -571	-7%	-$27.5K	0.05%	146
2025 Q3	$344K	Sell	7,635 -73	-0.9%	-$3.41K	0.05%	147
2025 Q2	$357K	Sell	7,708 -16,244	-68%	-$797K	0.05%	142
2025 Q1	$1.46M	Sell	23,952 -1,155	-5%	-$67.3K	0.23%	97
2024 Q4	$1.42M	Sell	25,107 -1,901	-7%	-$106K	0.23%	101
2024 Q3	$1.4M	Sell	27,008 -3,644	-12%	-$171K	0.21%	101
2024 Q2	$1.27M	Sell	30,652 -1,326	-4%	-$59.3K	0.2%	102
2024 Q1	$1.73M	Sell	31,978 -5,413	-14%	-$276K	0.28%	85
2023 Q4	$1.92M	Buy	+37,391	New	+$1.96M	0.31%	73

Other funds holding BMY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

AIM

Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

DLA

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Arvest Investments's BMY Position: Q2 2026 in Review

Arvest Investments reduced its Bristol-Myers Squibb (BMY) stake by 1.8% in Q2 2026, selling an estimated $7.24K and leaving 6,805 shares worth $392K. The position accounts for 0.05% of the portfolio, ranked #158.

Arvest Investments first reported a position in BMY in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.92M in Q4 2023. 889 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

Arvest Investments held 6,805 shares of Bristol-Myers Squibb worth $392K as of Q2 2026.
Arvest Investments sold 126 Bristol-Myers Squibb shares in Q2 2026, an estimated $7.24K.
Bristol-Myers Squibb made up 0.05% of Arvest Investments's portfolio in Q2 2026, its #158 holding.
Arvest Investments first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 11 quarters since.
Arvest Investments's Bristol-Myers Squibb position peaked at $1.92M in Q4 2023.
889 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Arvest Investments's 13F filing for Q2 2026, filed 17 Jul 2026.